Article Details

Sucampo Pharmaceuticals (NASDAQ:SCMP) Upgraded to Buy at Zacks Investment Research

Retrieved on: 2018-02-15 18:18:45

Tags for this article:

Click the tags to see associated articles and topics

Sucampo Pharmaceuticals (NASDAQ:SCMP) Upgraded to Buy at Zacks Investment Research. View article details on hiswai:

Excerpt

<div>Finally, <b>Two Sigma Investments</b> LP raised its holdings in shares of Sucampo Pharmaceuticals by 1,013.8% in the 4th quarter. <b>Two Sigma Investments</b> LP now owns 548,672 shares of the biopharmaceutical company's stock valued at $9,849,000 after purchasing an additional 499,409 shares in the last ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up